Contribution of pks+ Escherichia coli (E. coli) to Colon Carcinogenesis
Microorganisms · 30.05.2024 · 12 (6) · 1111
DOI: 10.3390/microorganisms12061111 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 30.05.2024. Verfasst von Mohammad Sadeghi und 2 weiteren Autor:innen. Beteiligte Einrichtung: EA7375-EC2M3: Early, Detection of Colonic Cancer by Using Microbial & Molecular Markers, Paris East Créteil University (UPEC), 94010 Créteil, France. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Mayo Clinic in Arizona, EPIMECHA.
Abstract (Originalsprache)
Colorectal cancer (CRC) stands as a significant global health concern, ranking second in mortality and third in frequency among cancers worldwide. While only a small fraction of CRC cases can be attributed to inherited genetic mutations, the majority arise sporadically due to somatic mutations. Emerging evidence reveals gut microbiota dysbiosis to be a contributing factor, wherein polyketide synthase-positive Escherichia coli (pks+ E. coli) plays a pivotal role in CRC pathogenesis. pks+ bacteria produce colibactin, a genotoxic protein that causes deleterious effects on DNA within host colonocytes. In this review, we examine the role of the gut microbiota in colon carcinogenesis, elucidating how colibactin-producer bacteria induce DNA damage, promote genomic instability, disrupt the gut epithelial barrier, induce mucosal inflammation, modulate host immune responses, and influence cell cycle dynamics. Collectively, these actions foster a microenvironment conducive to tumor initiation and progression. Understanding the mechanisms underlying pks+ bacteria-mediated CRC development may pave the way for mass screening, early detection of tumors, and therapeutic strategies such as microbiota modulation, bacteria-targeted therapy, checkpoint inhibition of colibactin production and immunomodulatory pathways.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- EA7375-EC2M3: Early, Detection of Colonic Cancer by Using Microbial & Molecular Markers, Paris East Créteil University (UPEC), 94010 Créteil, France.
- Department of Gastroenterology, Assistance Publique-Hôpitaux de Paris (APHP), Henri Mondor Hospital, 94010 Créteil, France.
ORCID-Profile: Mohammad Sadeghi, Denis Mestivier, Iradj Sobhani
Förderung
- NCI NIH HHS
- Mayo Clinic in Arizona
- EPIMECHA
- MicroTEND study (GTE French Gastrointestinal endocrine tumours)
- National Institutes of Health
Zitieren
APA
Sadeghi, M., Mestivier, D., & Sobhani, I. (2024). Contribution of pks+ Escherichia coli (E. coli) to Colon Carcinogenesis. Microorganisms, 12(6), 1111. https://doi.org/10.3390/microorganisms12061111
Vancouver
Sadeghi M, Mestivier D, Sobhani I. Contribution of pks+ Escherichia coli (E. coli) to Colon Carcinogenesis. Microorganisms. 2024;12(6):1111. doi:10.3390/microorganisms12061111
BibTeX
@article{Sadeghi2024,
author = {Sadeghi, Mohammad and Mestivier, Denis and Sobhani, Iradj},
title = {Contribution of pks+ Escherichia coli (E. coli) to Colon Carcinogenesis},
journal = {Microorganisms},
year = {2024},
volume = {12},
number = {6},
pages = {1111},
doi = {10.3390/microorganisms12061111}
}
EUVIMED